Neuland Laboratories Limited has submitted a regulatory filing to BSE Limited and the National Stock Exchange of India Ltd intimating them about its upcoming Q1 FY 2027 Earnings Conference Call. The disclosure is made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015.
The document includes extensive background information about the company's operations. Neuland Laboratories has been manufacturing APIs for over 4 decades through its cGMP manufacturing facilities and serves customers in close to 80 countries. The company has developed more than 300 processes and 100 APIs, with approximately 1010 regulatory filings across various geographies.
Notable regulatory certifications include: U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI"SID & GP"Russia, Health Canada, ISO 9001, ISO14001, OHSAS18001 and ISO 27001.
The filing provides specific investor relations contact information for earnings call queries:
- Neuland Labs IR: ir@neulandlabs.com
- Runjhun Jain: 98207 20993 / Runjhun.Jain1@in.ey.com
- Minakshi Machutre: 98671 44505 / Minakshi.machutre@in.ey.com
The document was digitally signed by Sarada Bhamidipati, Company Secretary of Neuland Laboratories Limited, on July 28, 2026 at 11:41:13 IST.